Molecular Mechanisms of Cardiac Amyloidosis

Cardiac involvement has a profound effect on the prognosis of patients with systemic amyloidosis. Therapeutic methods for suppressing the production of causative proteins have been developed for ATTR amyloidosis and AL amyloidosis, which show cardiac involvement, and the prognosis has been improved....

Descripción completa

Detalles Bibliográficos
Autores principales: Saito, Yukihiro, Nakamura, Kazufumi, Ito, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8744761/
https://www.ncbi.nlm.nih.gov/pubmed/35008444
http://dx.doi.org/10.3390/ijms23010025
_version_ 1784630185941794816
author Saito, Yukihiro
Nakamura, Kazufumi
Ito, Hiroshi
author_facet Saito, Yukihiro
Nakamura, Kazufumi
Ito, Hiroshi
author_sort Saito, Yukihiro
collection PubMed
description Cardiac involvement has a profound effect on the prognosis of patients with systemic amyloidosis. Therapeutic methods for suppressing the production of causative proteins have been developed for ATTR amyloidosis and AL amyloidosis, which show cardiac involvement, and the prognosis has been improved. However, a method for removing deposited amyloid has not been established. Methods for reducing cytotoxicity caused by amyloid deposition and amyloid precursor protein to protect cardiovascular cells are also needed. In this review, we outline the molecular mechanisms and treatments of cardiac amyloidosis.
format Online
Article
Text
id pubmed-8744761
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87447612022-01-11 Molecular Mechanisms of Cardiac Amyloidosis Saito, Yukihiro Nakamura, Kazufumi Ito, Hiroshi Int J Mol Sci Review Cardiac involvement has a profound effect on the prognosis of patients with systemic amyloidosis. Therapeutic methods for suppressing the production of causative proteins have been developed for ATTR amyloidosis and AL amyloidosis, which show cardiac involvement, and the prognosis has been improved. However, a method for removing deposited amyloid has not been established. Methods for reducing cytotoxicity caused by amyloid deposition and amyloid precursor protein to protect cardiovascular cells are also needed. In this review, we outline the molecular mechanisms and treatments of cardiac amyloidosis. MDPI 2021-12-21 /pmc/articles/PMC8744761/ /pubmed/35008444 http://dx.doi.org/10.3390/ijms23010025 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Saito, Yukihiro
Nakamura, Kazufumi
Ito, Hiroshi
Molecular Mechanisms of Cardiac Amyloidosis
title Molecular Mechanisms of Cardiac Amyloidosis
title_full Molecular Mechanisms of Cardiac Amyloidosis
title_fullStr Molecular Mechanisms of Cardiac Amyloidosis
title_full_unstemmed Molecular Mechanisms of Cardiac Amyloidosis
title_short Molecular Mechanisms of Cardiac Amyloidosis
title_sort molecular mechanisms of cardiac amyloidosis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8744761/
https://www.ncbi.nlm.nih.gov/pubmed/35008444
http://dx.doi.org/10.3390/ijms23010025
work_keys_str_mv AT saitoyukihiro molecularmechanismsofcardiacamyloidosis
AT nakamurakazufumi molecularmechanismsofcardiacamyloidosis
AT itohiroshi molecularmechanismsofcardiacamyloidosis

Ejemplares similares